查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1576568

貝特類藥物市場：按藥物類型、應用、患者屬性、分銷管道、劑型、最終用戶、給藥途徑和購買模式分類的全球預測 - 2025-2030

Fibrate Drugs Market by Drug Type, Application, Patient Demographics, Distribution Channel, Formulation, End User, Route Of Administration, Mode Of Purchase - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年，貝特類藥物市值為34.5億美元，預計到2024年將達到37.2億美元，複合年成長率為7.05%，到2030年將達到55.6億美元。

貝特類藥物市場主要集中在透過降低三酸甘油酯水平和增加高密度脂蛋白（HDL）膽固醇來治療血脂血脂異常症的調脂藥物。貝特類藥物的需求在於其在管理與高血脂症相關的心血管危險因子方面的有效性，特別是對於無法使用他汀類藥物或他汀類藥物療效不足的患者。貝特類藥物的主要用途包括單一療法或與其他降脂療法合併治療高三酸甘油脂血症和混合型血脂異常等病症。主要使用範圍為醫院、診所等醫療機構，以及僅靠生活方式介入無法滿足治療要求時的私人處方。

主要市場統計
基準年[2023] 34.5億美元
預測年份 [2024] 37.2億美元
預測年份 [2030] 55.6億美元
複合年成長率（%） 7.05%

市場成長受到全球心血管疾病和肥胖症發病率上升、老年人口數量增加以及人們對預防性醫療保健措施意識不斷增強的影響。不斷增加的市場開拓和新藥核准也為該市場提供了利潤豐厚的機會。然而，潛在的成長受到胃腸道不適和肝毒性等副作用以及來自他汀類藥物等更成熟的降膽固醇藥物的競爭的限制，後者通常具有更有利的副作用。

為了利用成長機會，公司應專注於嚴格的研究和開發，旨在提高貝特類藥物的安全性和有效性。開發可最大限度減少副作用的聯合治療和探索個人化醫療方法等創新可以提供競爭優勢。此外，透過策略夥伴關係和對新興市場的投資擴大市場進入可以擴大我們的消費者基礎。也必須謹慎應對嚴格的監管要求和專利到期等挑戰。公司應透過確保合規性來確保貝特類市場空間的持續成長和發展，同時繼續將製藥進步與未滿足的臨床需求結合。

市場動態：快速發展的貝特類市場的關鍵市場洞察

供需的動態交互作用正在改變貝特類市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，並了解消費行為及其對製造成本的影響，並更清楚地了解對採購趨勢的影響。

  • 市場促進因素
    • 成人和老年人群中高血脂症患者迅速增加
    • 製藥公司進軍潛力開拓的新興市場
    • 增強貝特類藥物療效的藥物傳遞系統的進展
    • 增加醫療保健支出和使用現代化醫療設施的機會
  • 市場限制因素
    • 新貝特製劑和變體的研發高成本
  • 市場機會
    • 針對脂質代謝相關遺傳疾病的貝特類藥物的利基市場
    • 有機會透過貝特類藥物個人化客製化患者治療計劃
    • 獸醫高血脂症治療對貝特類藥物的需求
  • 市場挑戰
    • 影響各地區貝特類核准流程的嚴格監管指南

波特五力：駕馭貝特類市場的策略工具

波特的五力架構是了解貝特類藥物市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解貝特類藥物市場的外部影響

外部宏觀環境因素對貝特類藥物市場的表現動態起著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解貝特類藥物市場競爭狀況

對貝特類藥物市場的詳細市場佔有率分析可以對供應商的表現進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的見解，以應對日益激烈的競爭。

FPNV定位矩陣貝特類市場供應商績效評估

FPNV定位矩陣是評估fibrate市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，以確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議，規劃貝特類藥物市場的成功之路

對於希望加強在全球市場的影響力的公司來說，對貝特類藥物市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 成人和老年人高血脂症病例迅速增加
      • 製藥公司在有潛力的新興市場擴張
      • 藥物輸送系統的進步提高了貝特類藥物的療效
      • 醫療保健成本上升和現代醫療設施的普及
    • 抑制因素
      • 新貝特製劑和變體的研發高成本
    • 機會
      • 針對脂質代謝相關遺傳疾病的貝特類藥物的利基市場
      • 使用貝特類藥物進行個人化醫療為患者量身定做治療計劃的機會
      • 治療動物高血脂症的獸藥對貝特類藥物的需求
    • 任務
      • 嚴格的監管指引影響了各地區貝特類藥物的核准流程
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章 貝特類藥物市場（依類型）

  • 苯札貝特
  • 安妥貝特
  • 非諾貝特
    • 非專利學名藥
  • 吉非貝齊

第7章貝特類藥物市場：依應用分類

  • 心血管疾病
  • 血脂異常症
  • 高血脂症
  • 高三酸甘油脂血症

第 8 章依病患分層分類的貝特類藥物市場

  • 成人
  • 老年人
  • 小兒科

第9章貝特類藥物市場：依通路分類

  • 藥局
  • 醫院藥房
  • 網路藥房
  • 零售藥房

第10章 貝特類處方藥市場

  • 膠囊
  • 暫停
  • 藥片

第11章貝特藥物市場：依最終使用者分類

  • 診所
  • 居家護理
  • 醫院

第12章貝特類藥物市場：依給藥途徑

  • 可注射的
  • 口服

第13章 貝特類藥物市場（依採購方式）

  • 在商店
  • 根據處方箋

第14章 北美及南美貝特類藥物市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第15章亞太地區貝特類藥物市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第16章 歐洲、中東和非洲貝特類藥物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第17章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議
Product Code: MRR-1A1A064C0478

The Fibrate Drugs Market was valued at USD 3.45 billion in 2023, expected to reach USD 3.72 billion in 2024, and is projected to grow at a CAGR of 7.05%, to USD 5.56 billion by 2030.

The fibrate drugs market is defined by its focus on lipid-modifying agents primarily used to treat dyslipidemia by lowering triglyceride levels and increasing high-density lipoprotein (HDL) cholesterol. The necessity for fibrate drugs lies in their effectiveness in managing cardiovascular risk factors associated with hyperlipidemia, especially for patients who cannot use or do not respond sufficiently to statins. Key applications of fibrate drugs include their use as standalone treatments or in combination with other lipid-lowering therapies in the management of conditions like hypertriglyceridemia and mixed dyslipidemia. End-use scope predominantly involves medical institutions, including hospitals and clinics, along with individual prescriptions where lifestyle interventions alone do not meet therapeutic requirements.

KEY MARKET STATISTICS
Base Year [2023] USD 3.45 billion
Estimated Year [2024] USD 3.72 billion
Forecast Year [2030] USD 5.56 billion
CAGR (%) 7.05%

Market growth is influenced by the rise in global cases of cardiovascular diseases and obesity, a growing geriatric population, and increased awareness about preventative healthcare measures. The rise in drug development and approval of novel therapies also presents lucrative opportunities in this market. However, potential growth is limited by side effects such as gastrointestinal discomfort or liver toxicity and the competition from more established cholesterol-lowering agents like statins, which often have a more favorable side effect profile.

To exploit growth opportunities, companies should focus on rigorous research and development aimed at enhancing the safety and efficacy profile of fibrate drugs. Innovations like developing combination therapies that minimize side effects or exploring personalized medicine approaches could provide competitive advantages. Furthermore, expanding market access through strategic partnerships and investments in emerging markets can broaden the consumer base. Challenges such as stringent regulatory requirements and patent expirations also need to be navigated carefully. Businesses should ensure compliance while continuously seeking to align pharmaceutical advancements with unmet clinical needs, thereby ensuring sustainable growth and development in the fibrate drugs market domain.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Fibrate Drugs Market

The Fibrate Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Surging cases of hyperlipidemia among adult and geriatric population
    • Expansion of pharmaceutical companies in emerging markets with untapped potential
    • Advancements in drug delivery systems enhancing the efficacy of fibrate drugs
    • Rise in healthcare expenditure and access to modern medical facilities
  • Market Restraints
    • High costs associated with research and development of new fibrate formulations and variants
  • Market Opportunities
    • Niche market for fibrate drugs targeting genetic disorders involving lipid metabolism
    • Opportunities in personalized medicine through fibrate drugs for customized patient treatment plans
    • Demand for fibrate drugs in veterinary medicine for treating hyperlipidemia in animals
  • Market Challenges
    • Strict regulatory guidelines impacting the approval process of fibrate drugs in different regions

Porter's Five Forces: A Strategic Tool for Navigating the Fibrate Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Fibrate Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Fibrate Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Fibrate Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Fibrate Drugs Market

A detailed market share analysis in the Fibrate Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Fibrate Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Fibrate Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Fibrate Drugs Market

A strategic analysis of the Fibrate Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Fibrate Drugs Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Allergan plc, Amgen Inc., AstraZeneca plc, Aurobindo Pharma Limited, Bristol-Myers Squibb Company, Cipla Limited, Daiichi Sankyo Company, Limited, GlaxoSmithKline plc, Lupin Limited, Merck & Co., Inc., Mylan N.V., Novartis AG, Pfizer Inc., Sanofi S.A., Sun Pharmaceutical Industries Limited, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Limited, and Zydus Cadila.

Market Segmentation & Coverage

This research report categorizes the Fibrate Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug Type, market is studied across Bezafibrate, Clofibrate, Fenofibrate, and Gemfibrozil. The Fenofibrate is further studied across Generic Fenofibrate.
  • Based on Application, market is studied across Cardiovascular Diseases, Dyslipidemia, Hyperlipidemia, and Hypertriglyceridemia.
  • Based on Patient Demographics, market is studied across Adults, Elderly, and Pediatric.
  • Based on Distribution Channel, market is studied across Drug Stores, Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
  • Based on Formulation, market is studied across Capsules, Suspensions, and Tablets.
  • Based on End User, market is studied across Clinics, Homecare, and Hospitals.
  • Based on Route Of Administration, market is studied across Injectable and Oral.
  • Based on Mode Of Purchase, market is studied across Over The Counter and Prescription Based.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Surging cases of hyperlipidemia among adult and geriatric population
      • 5.1.1.2. Expansion of pharmaceutical companies in emerging markets with untapped potential
      • 5.1.1.3. Advancements in drug delivery systems enhancing the efficacy of fibrate drugs
      • 5.1.1.4. Rise in healthcare expenditure and access to modern medical facilities
    • 5.1.2. Restraints
      • 5.1.2.1. High costs associated with research and development of new fibrate formulations and variants
    • 5.1.3. Opportunities
      • 5.1.3.1. Niche market for fibrate drugs targeting genetic disorders involving lipid metabolism
      • 5.1.3.2. Opportunities in personalized medicine through fibrate drugs for customized patient treatment plans
      • 5.1.3.3. Demand for fibrate drugs in veterinary medicine for treating hyperlipidemia in animals
    • 5.1.4. Challenges
      • 5.1.4.1. Strict regulatory guidelines impacting the approval process of fibrate drugs in different regions
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Fibrate Drugs Market, by Drug Type

  • 6.1. Introduction
  • 6.2. Bezafibrate
  • 6.3. Clofibrate
  • 6.4. Fenofibrate
    • 6.4.1. Generic Fenofibrate
  • 6.5. Gemfibrozil

7. Fibrate Drugs Market, by Application

  • 7.1. Introduction
  • 7.2. Cardiovascular Diseases
  • 7.3. Dyslipidemia
  • 7.4. Hyperlipidemia
  • 7.5. Hypertriglyceridemia

8. Fibrate Drugs Market, by Patient Demographics

  • 8.1. Introduction
  • 8.2. Adults
  • 8.3. Elderly
  • 8.4. Pediatric

9. Fibrate Drugs Market, by Distribution Channel

  • 9.1. Introduction
  • 9.2. Drug Stores
  • 9.3. Hospital Pharmacies
  • 9.4. Online Pharmacies
  • 9.5. Retail Pharmacies

10. Fibrate Drugs Market, by Formulation

  • 10.1. Introduction
  • 10.2. Capsules
  • 10.3. Suspensions
  • 10.4. Tablets

11. Fibrate Drugs Market, by End User

  • 11.1. Introduction
  • 11.2. Clinics
  • 11.3. Homecare
  • 11.4. Hospitals

12. Fibrate Drugs Market, by Route Of Administration

  • 12.1. Introduction
  • 12.2. Injectable
  • 12.3. Oral

13. Fibrate Drugs Market, by Mode Of Purchase

  • 13.1. Introduction
  • 13.2. Over The Counter
  • 13.3. Prescription Based

14. Americas Fibrate Drugs Market

  • 14.1. Introduction
  • 14.2. Argentina
  • 14.3. Brazil
  • 14.4. Canada
  • 14.5. Mexico
  • 14.6. United States

15. Asia-Pacific Fibrate Drugs Market

  • 15.1. Introduction
  • 15.2. Australia
  • 15.3. China
  • 15.4. India
  • 15.5. Indonesia
  • 15.6. Japan
  • 15.7. Malaysia
  • 15.8. Philippines
  • 15.9. Singapore
  • 15.10. South Korea
  • 15.11. Taiwan
  • 15.12. Thailand
  • 15.13. Vietnam

16. Europe, Middle East & Africa Fibrate Drugs Market

  • 16.1. Introduction
  • 16.2. Denmark
  • 16.3. Egypt
  • 16.4. Finland
  • 16.5. France
  • 16.6. Germany
  • 16.7. Israel
  • 16.8. Italy
  • 16.9. Netherlands
  • 16.10. Nigeria
  • 16.11. Norway
  • 16.12. Poland
  • 16.13. Qatar
  • 16.14. Russia
  • 16.15. Saudi Arabia
  • 16.16. South Africa
  • 16.17. Spain
  • 16.18. Sweden
  • 16.19. Switzerland
  • 16.20. Turkey
  • 16.21. United Arab Emirates
  • 16.22. United Kingdom

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2023
  • 17.2. FPNV Positioning Matrix, 2023
  • 17.3. Competitive Scenario Analysis
  • 17.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Allergan plc
  • 3. Amgen Inc.
  • 4. AstraZeneca plc
  • 5. Aurobindo Pharma Limited
  • 6. Bristol-Myers Squibb Company
  • 7. Cipla Limited
  • 8. Daiichi Sankyo Company, Limited
  • 9. GlaxoSmithKline plc
  • 10. Lupin Limited
  • 11. Merck & Co., Inc.
  • 12. Mylan N.V.
  • 13. Novartis AG
  • 14. Pfizer Inc.
  • 15. Sanofi S.A.
  • 16. Sun Pharmaceutical Industries Limited
  • 17. Takeda Pharmaceutical Company Limited
  • 18. Teva Pharmaceutical Industries Ltd.
  • 19. Torrent Pharmaceuticals Limited
  • 20. Zydus Cadila

LIST OF FIGURES

  • FIGURE 1. FIBRATE DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. FIBRATE DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL FIBRATE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL FIBRATE DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL FIBRATE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL FIBRATE DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL FIBRATE DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL FIBRATE DRUGS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL FIBRATE DRUGS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL FIBRATE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL FIBRATE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL FIBRATE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL FIBRATE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL FIBRATE DRUGS MARKET SIZE, BY FORMULATION, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL FIBRATE DRUGS MARKET SIZE, BY FORMULATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. GLOBAL FIBRATE DRUGS MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 17. GLOBAL FIBRATE DRUGS MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. GLOBAL FIBRATE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 19. GLOBAL FIBRATE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. GLOBAL FIBRATE DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2023 VS 2030 (%)
  • FIGURE 21. GLOBAL FIBRATE DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. AMERICAS FIBRATE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. AMERICAS FIBRATE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. UNITED STATES FIBRATE DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 25. UNITED STATES FIBRATE DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 26. ASIA-PACIFIC FIBRATE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 27. ASIA-PACIFIC FIBRATE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 28. EUROPE, MIDDLE EAST & AFRICA FIBRATE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 29. EUROPE, MIDDLE EAST & AFRICA FIBRATE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 30. FIBRATE DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 31. FIBRATE DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. FIBRATE DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL FIBRATE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL FIBRATE DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL FIBRATE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. FIBRATE DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL FIBRATE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL FIBRATE DRUGS MARKET SIZE, BY BEZAFIBRATE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL FIBRATE DRUGS MARKET SIZE, BY CLOFIBRATE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL FIBRATE DRUGS MARKET SIZE, BY FENOFIBRATE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL FIBRATE DRUGS MARKET SIZE, BY GENERIC FENOFIBRATE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL FIBRATE DRUGS MARKET SIZE, BY FENOFIBRATE, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL FIBRATE DRUGS MARKET SIZE, BY GEMFIBROZIL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL FIBRATE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL FIBRATE DRUGS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL FIBRATE DRUGS MARKET SIZE, BY DYSLIPIDEMIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL FIBRATE DRUGS MARKET SIZE, BY HYPERLIPIDEMIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL FIBRATE DRUGS MARKET SIZE, BY HYPERTRIGLYCERIDEMIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL FIBRATE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL FIBRATE DRUGS MARKET SIZE, BY ADULTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL FIBRATE DRUGS MARKET SIZE, BY ELDERLY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL FIBRATE DRUGS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL FIBRATE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL FIBRATE DRUGS MARKET SIZE, BY DRUG STORES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL FIBRATE DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL FIBRATE DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL FIBRATE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL FIBRATE DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL FIBRATE DRUGS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL FIBRATE DRUGS MARKET SIZE, BY SUSPENSIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL FIBRATE DRUGS MARKET SIZE, BY TABLETS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL FIBRATE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL FIBRATE DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL FIBRATE DRUGS MARKET SIZE, BY HOMECARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL FIBRATE DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL FIBRATE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL FIBRATE DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL FIBRATE DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL FIBRATE DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL FIBRATE DRUGS MARKET SIZE, BY OVER THE COUNTER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL FIBRATE DRUGS MARKET SIZE, BY PRESCRIPTION BASED, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 42. AMERICAS FIBRATE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. AMERICAS FIBRATE DRUGS MARKET SIZE, BY FENOFIBRATE, 2018-2030 (USD MILLION)
  • TABLE 44. AMERICAS FIBRATE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 45. AMERICAS FIBRATE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 46. AMERICAS FIBRATE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 47. AMERICAS FIBRATE DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 48. AMERICAS FIBRATE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 49. AMERICAS FIBRATE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 50. AMERICAS FIBRATE DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
  • TABLE 51. AMERICAS FIBRATE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 52. ARGENTINA FIBRATE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. ARGENTINA FIBRATE DRUGS MARKET SIZE, BY FENOFIBRATE, 2018-2030 (USD MILLION)
  • TABLE 54. ARGENTINA FIBRATE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 55. ARGENTINA FIBRATE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 56. ARGENTINA FIBRATE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 57. ARGENTINA FIBRATE DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 58. ARGENTINA FIBRATE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 59. ARGENTINA FIBRATE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 60. ARGENTINA FIBRATE DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
  • TABLE 61. BRAZIL FIBRATE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. BRAZIL FIBRATE DRUGS MARKET SIZE, BY FENOFIBRATE, 2018-2030 (USD MILLION)
  • TABLE 63. BRAZIL FIBRATE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 64. BRAZIL FIBRATE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 65. BRAZIL FIBRATE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 66. BRAZIL FIBRATE DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 67. BRAZIL FIBRATE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 68. BRAZIL FIBRATE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 69. BRAZIL FIBRATE DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
  • TABLE 70. CANADA FIBRATE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. CANADA FIBRATE DRUGS MARKET SIZE, BY FENOFIBRATE, 2018-2030 (USD MILLION)
  • TABLE 72. CANADA FIBRATE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 73. CANADA FIBRATE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 74. CANADA FIBRATE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 75. CANADA FIBRATE DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 76. CANADA FIBRATE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 77. CANADA FIBRATE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 78. CANADA FIBRATE DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
  • TABLE 79. MEXICO FIBRATE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. MEXICO FIBRATE DRUGS MARKET SIZE, BY FENOFIBRATE, 2018-2030 (USD MILLION)
  • TABLE 81. MEXICO FIBRATE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 82. MEXICO FIBRATE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 83. MEXICO FIBRATE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 84. MEXICO FIBRATE DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 85. MEXICO FIBRATE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 86. MEXICO FIBRATE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 87. MEXICO FIBRATE DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
  • TABLE 88. UNITED STATES FIBRATE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. UNITED STATES FIBRATE DRUGS MARKET SIZE, BY FENOFIBRATE, 2018-2030 (USD MILLION)
  • TABLE 90. UNITED STATES FIBRATE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 91. UNITED STATES FIBRATE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 92. UNITED STATES FIBRATE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 93. UNITED STATES FIBRATE DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 94. UNITED STATES FIBRATE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 95. UNITED STATES FIBRATE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 96. UNITED STATES FIBRATE DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
  • TABLE 97. UNITED STATES FIBRATE DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC FIBRATE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. ASIA-PACIFIC FIBRATE DRUGS MARKET SIZE, BY FENOFIBRATE, 2018-2030 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC FIBRATE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 101. ASIA-PACIFIC FIBRATE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 102. ASIA-PACIFIC FIBRATE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC FIBRATE DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 104. ASIA-PACIFIC FIBRATE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 105. ASIA-PACIFIC FIBRATE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 106. ASIA-PACIFIC FIBRATE DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
  • TABLE 107. ASIA-PACIFIC FIBRATE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 108. AUSTRALIA FIBRATE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. AUSTRALIA FIBRATE DRUGS MARKET SIZE, BY FENOFIBRATE, 2018-2030 (USD MILLION)
  • TABLE 110. AUSTRALIA FIBRATE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 111. AUSTRALIA FIBRATE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 112. AUSTRALIA FIBRATE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 113. AUSTRALIA FIBRATE DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 114. AUSTRALIA FIBRATE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 115. AUSTRALIA FIBRATE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 116. AUSTRALIA FIBRATE DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
  • TABLE 117. CHINA FIBRATE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. CHINA FIBRATE DRUGS MARKET SIZE, BY FENOFIBRATE, 2018-2030 (USD MILLION)
  • TABLE 119. CHINA FIBRATE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 120. CHINA FIBRATE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 121. CHINA FIBRATE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 122. CHINA FIBRATE DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 123. CHINA FIBRATE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 124. CHINA FIBRATE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 125. CHINA FIBRATE DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
  • TABLE 126. INDIA FIBRATE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. INDIA FIBRATE DRUGS MARKET SIZE, BY FENOFIBRATE, 2018-2030 (USD MILLION)
  • TABLE 128. INDIA FIBRATE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 129. INDIA FIBRATE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 130. INDIA FIBRATE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 131. INDIA FIBRATE DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 132. INDIA FIBRATE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 133. INDIA FIBRATE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 134. INDIA FIBRATE DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
  • TABLE 135. INDONESIA FIBRATE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. INDONESIA FIBRATE DRUGS MARKET SIZE, BY FENOFIBRATE, 2018-2030 (USD MILLION)
  • TABLE 137. INDONESIA FIBRATE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 138. INDONESIA FIBRATE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 139. INDONESIA FIBRATE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 140. INDONESIA FIBRATE DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 141. INDONESIA FIBRATE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 142. INDONESIA FIBRATE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 143. INDONESIA FIBRATE DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
  • TABLE 144. JAPAN FIBRATE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. JAPAN FIBRATE DRUGS MARKET SIZE, BY FENOFIBRATE, 2018-2030 (USD MILLION)
  • TABLE 146. JAPAN FIBRATE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 147. JAPAN FIBRATE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 148. JAPAN FIBRATE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 149. JAPAN FIBRATE DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 150. JAPAN FIBRATE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 151. JAPAN FIBRATE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 152. JAPAN FIBRATE DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
  • TABLE 153. MALAYSIA FIBRATE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 154. MALAYSIA FIBRATE DRUGS MARKET SIZE, BY FENOFIBRATE, 2018-2030 (USD MILLION)
  • TABLE 155. MALAYSIA FIBRATE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 156. MALAYSIA FIBRATE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 157. MALAYSIA FIBRATE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 158. MALAYSIA FIBRATE DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 159. MALAYSIA FIBRATE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 160. MALAYSIA FIBRATE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 161. MALAYSIA FIBRATE DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
  • TABLE 162. PHILIPPINES FIBRATE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 163. PHILIPPINES FIBRATE DRUGS MARKET SIZE, BY FENOFIBRATE, 2018-2030 (USD MILLION)
  • TABLE 164. PHILIPPINES FIBRATE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 165. PHILIPPINES FIBRATE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 166. PHILIPPINES FIBRATE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 167. PHILIPPINES FIBRATE DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 168. PHILIPPINES FIBRATE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 169. PHILIPPINES FIBRATE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 170. PHILIPPINES FIBRATE DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
  • TABLE 171. SINGAPORE FIBRATE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 172. SINGAPORE FIBRATE DRUGS MARKET SIZE, BY FENOFIBRATE, 2018-2030 (USD MILLION)
  • TABLE 173. SINGAPORE FIBRATE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 174. SINGAPORE FIBRATE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 175. SINGAPORE FIBRATE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 176. SINGAPORE FIBRATE DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 177. SINGAPORE FIBRATE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 178. SINGAPORE FIBRATE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 179. SINGAPORE FIBRATE DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
  • TABLE 180. SOUTH KOREA FIBRATE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 181. SOUTH KOREA FIBRATE DRUGS MARKET SIZE, BY FENOFIBRATE, 2018-2030 (USD MILLION)
  • TABLE 182. SOUTH KOREA FIBRATE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 183. SOUTH KOREA FIBRATE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 184. SOUTH KOREA FIBRATE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 185. SOUTH KOREA FIBRATE DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 186. SOUTH KOREA FIBRATE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 187. SOUTH KOREA FIBRATE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 188. SOUTH KOREA FIBRATE DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
  • TABLE 189. TAIWAN FIBRATE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 190. TAIWAN FIBRATE DRUGS MARKET SIZE, BY FENOFIBRATE, 2018-2030 (USD MILLION)
  • TABLE 191. TAIWAN FIBRATE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 192. TAIWAN FIBRATE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 193. TAIWAN FIBRATE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 194. TAIWAN FIBRATE DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 195. TAIWAN FIBRATE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 196. TAIWAN FIBRATE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 197. TAIWAN FIBRATE DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
  • TABLE 198. THAILAND FIBRATE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 199. THAILAND FIBRATE DRUGS MARKET SIZE, BY FENOFIBRATE, 2018-2030 (USD MILLION)
  • TABLE 200. THAILAND FIBRATE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 201. THAILAND FIBRATE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 202. THAILAND FIBRATE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 203. THAILAND FIBRATE DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 204. THAILAND FIBRATE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 205. THAILAND FIBRATE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 206. THAILAND FIBRATE DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
  • TABLE 207. VIETNAM FIBRATE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 208. VIETNAM FIBRATE DRUGS MARKET SIZE, BY FENOFIBRATE, 2018-2030 (USD MILLION)
  • TABLE 209. VIETNAM FIBRATE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 210. VIETNAM FIBRATE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 211. VIETNAM FIBRATE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 212. VIETNAM FIBRATE DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 213. VIETNAM FIBRATE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 214. VIETNAM FIBRATE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 215. VIETNAM FIBRATE DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
  • TABLE 216. EUROPE, MIDDLE EAST & AFRICA FIBRATE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 217. EUROPE, MIDDLE EAST & AFRICA FIBRATE DRUGS MARKET SIZE, BY FENOFIBRATE, 2018-2030 (USD MILLION)
  • TABLE 218. EUROPE, MIDDLE EAST & AFRICA FIBRATE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 219. EUROPE, MIDDLE EAST & AFRICA FIBRATE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 220. EUROPE, MIDDLE EAST & AFRICA FIBRATE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 221. EUROPE, MIDDLE EAST & AFRICA FIBRATE DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 222. EUROPE, MIDDLE EAST & AFRICA FIBRATE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 223. EUROPE, MIDDLE EAST & AFRICA FIBRATE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 224. EUROPE, MIDDLE EAST & AFRICA FIBRATE DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
  • TABLE 225. EUROPE, MIDDLE EAST & AFRICA FIBRATE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 226. DENMARK FIBRATE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 227. DENMARK FIBRATE DRUGS MARKET SIZE, BY FENOFIBRATE, 2018-2030 (USD MILLION)
  • TABLE 228. DENMARK FIBRATE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 229. DENMARK FIBRATE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 230. DENMARK FIBRATE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 231. DENMARK FIBRATE DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 232. DENMARK FIBRATE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 233. DENMARK FIBRATE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 234. DENMARK FIBRATE DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
  • TABLE 235. EGYPT FIBRATE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 236. EGYPT FIBRATE DRUGS MARKET SIZE, BY FENOFIBRATE, 2018-2030 (USD MILLION)
  • TABLE 237. EGYPT FIBRATE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 238. EGYPT FIBRATE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 239. EGYPT FIBRATE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 240. EGYPT FIBRATE DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 241. EGYPT FIBRATE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 242. EGYPT FIBRATE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 243. EGYPT FIBRATE DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
  • TABLE 244. FINLAND FIBRATE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 245. FINLAND FIBRATE DRUGS MARKET SIZE, BY FENOFIBRATE, 2018-2030 (USD MILLION)
  • TABLE 246. FINLAND FIBRATE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 247. FINLAND FIBRATE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 248. FINLAND FIBRATE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 249. FINLAND FIBRATE DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 250. FINLAND FIBRATE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 251. FINLAND FIBRATE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 252. FINLAND FIBRATE DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
  • TABLE 253. FRANCE FIBRATE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 254. FRANCE FIBRATE DRUGS MARKET SIZE, BY FENOFIBRATE, 2018-2030 (USD MILLION)
  • TABLE 255. FRANCE FIBRATE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 256. FRANCE FIBRATE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 257. FRANCE FIBRATE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 258. FRANCE FIBRATE DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 259. FRANCE FIBRATE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 260. FRANCE FIBRATE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 261. FRANCE FIBRATE DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
  • TABLE 262. GERMANY FIBRATE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 263. GERMANY FIBRATE DRUGS MARKET SIZE, BY FENOFIBRATE, 2018-2030 (USD MILLION)
  • TABLE 264. GERMANY FIBRATE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 265. GERMANY FIBRATE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 266. GERMANY FIBRATE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 267. GERMANY FIBRATE DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 268. GERMANY FIBRATE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 269. GERMANY FIBRATE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 270. GERMANY FIBRATE DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
  • TABLE 271. ISRAEL FIBRATE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 272. ISRAEL FIBRATE DRUGS MARKET SIZE, BY FENOFIBRATE, 2018-2030 (USD MILLION)
  • TABLE 273. ISRAEL FIBRATE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 274. ISRAEL FIBRATE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 275. ISRAEL FIBRATE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 276. ISRAEL FIBRATE DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 277. ISRAEL FIBRATE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 278. ISRAEL FIBRATE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 279. ISRAEL FIBRATE DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
  • TABLE 280. ITALY FIBRATE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 281. ITALY FIBRATE DRUGS MARKET SIZE, BY FENOFIBRATE, 2018-2030 (USD MILLION)
  • TABLE 282. ITALY FIBRATE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 283. ITALY FIBRATE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 284. ITALY FIBRATE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 285. ITALY FIBRATE DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 286. ITALY FIBRATE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 287. ITALY FIBRATE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 288. ITALY FIBRATE DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
  • TABLE 289. NETHERLANDS FIBRATE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 290. NETHERLANDS FIBRATE DRUGS MARKET SIZE, BY FENOFIBRATE, 2018-2030 (USD MILLION)
  • TABLE 291. NETHERLANDS FIBRATE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 292. NETHERLANDS FIBRATE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 293. NETHERLANDS FIBRATE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 294. NETHERLANDS FIBRATE DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 295. NETHERLANDS FIBRATE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 296. NETHERLANDS FIBRATE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 297. NETHERLANDS FIBRATE DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
  • TABLE 298. NIGERIA FIBRATE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 299. NIGERIA FIBRATE DRUGS MARKET SIZE, BY FENOFIBRATE, 2018-2030 (USD MILLION)
  • TABLE 300. NIGERIA FIBRATE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 301. NIGERIA FIBRATE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 302. NIGERIA FIBRATE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 303. NIGERIA FIBRATE DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 304. NIGERIA FIBRATE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 305. NIGERIA FIBRATE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 306. NIGERIA FIBRATE DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
  • TABLE 307. NORWAY FIBRATE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 308. NORWAY FIBRATE DRUGS MARKET SIZE, BY FENOFIBRATE, 2018-2030 (USD MILLION)
  • TABLE 309. NORWAY FIBRATE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 310. NORWAY FIBRATE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 311. NORWAY FIBRATE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 312. NORWAY FIBRATE DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 313. NORWAY FIBRATE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 314. NORWAY FIBRATE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 315. NORWAY FIBRATE DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
  • TABLE 316. POLAND FIBRATE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 317. POLAND FIBRATE DRUGS MARKET SIZE, BY FENOFIBRATE, 2018-2030 (USD MILLION)
  • TABLE 318. POLAND FIBRATE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 319. POLAND FIBRATE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 320. POLAND FIBRATE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 321. POLAND FIBRATE DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 322. POLAND FIBRATE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 323. POLAND FIBRATE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 324. POLAND FIBRATE DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
  • TABLE 325. QATAR FIBRATE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 326. QATAR FIBRATE DRUGS MARKET SIZE, BY FENOFIBRATE, 2018-2030 (USD MILLION)
  • TABLE 327. QATAR FIBRATE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 328. QATAR FIBRATE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 329. QATAR FIBRATE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 330. QATAR FIBRATE DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 331. QATAR FIBRATE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 332. QATAR FIBRATE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 333. QATAR FIBRATE DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
  • TABLE 334. RUSSIA FIBRATE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 335. RUSSIA FIBRATE DRUGS MARKET SIZE, BY FENOFIBRATE, 2018-2030 (USD MILLION)
  • TABLE 336. RUSSIA FIBRATE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 337. RUSSIA FIBRATE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 338. RUSSIA FIBRATE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 339. RUSSIA FIBRATE DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 340. RUSSIA FIBRATE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 341. RUSSIA FIBRATE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 342. RUSSIA FIBRATE DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
  • TABLE 343. SAUDI ARABIA FIBRATE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 344. SAUDI ARABIA FIBRATE DRUGS MARKET SIZE, BY FENOFIBRATE, 2018-2030 (USD MILLION)
  • TABLE 345. SAUDI ARABIA FIBRATE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 346. SAUDI ARABIA FIBRATE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 347. SAUDI ARABIA FIBRATE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 348. SAUDI ARABIA FIBRATE DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 349. SAUDI ARABIA FIBRATE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 350. SAUDI ARABIA FIBRATE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 351. SAUDI ARABIA FIBRATE DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
  • TABLE 352. SOUTH AFRICA FIBRATE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 353. SOUTH AFRICA FIBRATE DRUGS MARKET SIZE, BY FENOFIBRATE, 2018-2030 (USD MILLION)
  • TABLE 354. SOUTH AFRICA FIBRATE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 355. SOUTH AFRICA FIBRATE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 356. SOUTH AFRICA FIBRATE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 357. SOUTH AFRICA FIBRATE DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 358. SOUTH AFRICA FIBRATE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 359. SOUTH AFRICA FIBRATE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 360. SOUTH AFRICA FIBRATE DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
  • TABLE 361. SPAIN FIBRATE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 362. SPAIN FIBRATE DRUGS MARKET SIZE, BY FENOFIBRATE, 2018-2030 (USD MILLION)
  • TABLE 363. SPAIN FIBRATE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 364. SPAIN FIBRATE